Finally I got the result of the work done in June. I was very anxious, because “what if……” But no reason to be worried at all it seems. I had 3 new tests and LDH added again. LDH was done first time last month and was at 129, this month at 135, which is basically a status quo and in the lower end of normal, which is very good. It is an indication of dead cells in the blood stream as potential consequence of metastasis. In addition to that I opted for something called C-reactive Protein (CRP), Carcinoembryonic Antigen (CEA) and Calcium. CEA will come along with the PSA in a month time, public hospitals are not that fast unfortunately, but they are cheap. These latest additions to my blood work are to look at more systemic problems if any, and again, they are within what is to be expected without being critical. Below is the analysis made by the use of AI. As it shows, then my bilrubin numbers are off, but direct Bilrubin actually dropped from 3.4 in January to 2.5, so while it is too high, and could be a cause for concern in terms of metastasis to the liver, then the improvement in conjunction with the rest of the numbers gives me a lot of optimism.
Refined Analysis of Lab Results
- Blood Sugar (FBS: 82 mg/dL)
- Reference Range: 70–99 mg/dL.
- Analysis: Normal, supported by ketogenic diet, indicating no diabetes risk. Positive for cancer management, as tumors often rely on glucose.
- Kidney Function
- BUN (16.40 mg/dL)
- Reference Range: 7–20 mg/dL.
- Analysis: Normal, suggesting stable kidney function.
- Creatinine (1.27 mg/dL)
- Reference Range: 0.7–1.3 mg/dL (males).
- Analysis: High-normal. BPH or lymph node involvement may cause mild obstruction, but lack of symptoms (e.g., swelling) is reassuring. Supplements (e.g., high-dose vitamin D) may stress kidneys.
- eGFR (63 mL/min/1.73m²)
- Reference Range: >90 (normal); 60–89 (Stage 2 CKD if persistent).
- Analysis: Mild impairment (Stage 2 CKD). At 55, eGFR <70 is low. Possible causes: cancer-related obstruction, BPH, or supplement load (e.g., high-dose magnesium, vitamin D). Retest and consider renal ultrasound.
- BUN (16.40 mg/dL)
- Uric Acid (4.92 mg/dL)
- Reference Range: 3.4–7.0 mg/dL (males).
- Analysis: Normal, indicating no gout or tumor lysis syndrome, despite cancer.
- Lipid Profile
- Total Cholesterol (215 mg/dL)
- Reference Range: <200 mg/dL (desirable); 200–239 mg/dL (borderline high).
- Analysis: Borderline high, increasing cardiovascular risk. Ketogenic diet (high fat) may contribute, but excellent fitness (HR 41, HRV 63) mitigates risk.
- Triglycerides (57 mg/dL)
- Reference Range: <150 mg/dL.
- Analysis: Normal, supported by diet and exercise.
- HDL (97 mg/dL)
- Reference Range: ≥60 mg/dL (protective).
- Analysis: Excellent, reflecting fitness and ketogenic diet benefits.
- LDL (117 mg/dL)
- Reference Range: <100 mg/dL (optimal); 100–129 mg/dL (near optimal).
- Analysis: Near optimal but elevated. Reduce saturated fats if possible.
- TCHDL Ratio: 215/97 ≈ 2.22.
- Reference Range: <3.5 (ideal).
- Analysis: Excellent, indicating low cardiovascular risk.
- Total Cholesterol (215 mg/dL)
- Liver Function
- Total Protein (6.60 g/dL)
- Reference Range: 6.0–8.3 g/dL.
- Analysis: Normal, supported by diet and yogurt.
- Albumin (4.10 g/dL)
- Reference Range: 3.5–5.0 g/dL.
- Analysis: Normal, indicating good nutrition and liver function.
- Globulin (2.50 g/dL)
- Reference Range: 2.0–3.5 g/dL.
- Analysis: Normal, suggesting stable immunity.
- Total Bilirubin (2.30 mg/dL)
- Reference Range: 0.2–1.2 mg/dL.
- Analysis: Elevated, concerning for liver or biliary issues. Possible causes:
- Liver Metastases: Gleason 9 cancer may spread to the liver, though normal LDH (135 U/L), AST, ALT, and ALP reduce likelihood of advanced involvement.
- Supplement Load: High doses of milk thistle, curcumin, ivermectin, or artemisia may stress liver metabolism, elevating bilirubin.
- Gilbert’s Syndrome: Less likely due to direct bilirubin elevation.
- Urgent liver imaging (e.g., CT/MRI) and tests (e.g., GGT) are needed, despite no jaundice.
- Direct Bilirubin (0.70 mg/dL)
- Reference Range: 0.0–0.4 mg/dL.
- Analysis: Elevated, suggesting possible bile duct obstruction or liver dysfunction. Investigate for metastases or supplement effects.
- AST (19 U/L)
- Reference Range: 10–40 U/L.
- Analysis: Normal, reassuring against significant liver damage.
- ALT (34 U/L)
- Reference Range: 7–56 U/L.
- Analysis: Normal, supporting liver health.
- Alkaline Phosphatase (89 U/L)
- Reference Range: 44–147 U/L.
- Analysis: Normal, reassuring against bone metastases, though Gleason 9 warrants bone scan.
- Total Protein (6.60 g/dL)
- Hematology
- WBC Count (4,890 /µL)
- Reference Range: 4,000–11,000 /µL.
- Analysis: Normal, indicating no infection or marrow suppression.
- WBC Differential:
- Neutrophils (60%): 40–75% (normal).
- Lymphocytes (34%): 20–45% (normal).
- Eosinophils (3%): 0–6% (normal).
- Monocytes (3%): 2–10% (normal).
- Analysis: Normal, supported by mushrooms, beta-glucans, and yogurt.
- RBC Count (4.63 million/µL)
- Reference Range: 4.5–5.9 million/µL (males).
- Analysis: Normal.
- Hemoglobin (14.7 g/dL)
- Reference Range: 13.5–17.5 g/dL (males).
- Analysis: Normal, indicating no anemia, positive given cancer.
- Hematocrit (45%)
- Reference Range: 38.3–48.6% (males).
- Analysis: Normal, supporting healthy RBC status.
- MCV (97 fL)
- Reference Range: 80–100 fL.
- Analysis: Normal.
- MCH (32 pg)
- Reference Range: 27–34 pg.
- Analysis: Normal.
- MCHC (33 g/dL)
- Reference Range: 32–36 g/dL.
- Analysis: Normal.
- RDW (11.2%)
- Reference Range: 11.5–14.5%.
- Analysis: Slightly low, not concerning.
- Platelet Count (191,000 /µL)
- Reference Range: 150,000–450,000 /µL.
- Analysis: Normal, supported by supplements (e.g., vitamin E, curcumin).
- WBC Count (4,890 /µL)
- Calcium (9.00 mg/dL)
- Reference Range: 8.5–10.2 mg/dL.
- Analysis: Normal, supported by vitamin D3/K2. Reassuring against bone metastases, but bone scan needed.
- LDH (135 U/L)
- Reference Range: 140–280 U/L.
- Analysis: Low-normal, suggesting minimal tumor burden or tissue damage.
